당뇨병 : 최신 개발, 제품 혁신 및 치료

The global market for latest developments, product innovations, and treatments for diabetes was valued at $144.5 billion in 2025 and is estimated to increase from $162.2 billion in 2026 to reach $295 billion by the end of 2031, at a compound annual growth rate (CAGR) of 12.7% from 2026 to 2031.

Report Scope

The report provides an overview of the global market for latest developments, product innovations, and treatments for diabetes. It includes global revenue ($ million) using 2025 as the base year, estimated data for 2026, and projected data for 2026 through 2031.

By product, the market is segmented into diabetic pharmaceuticals, glucose monitoring device technologies, and insulin delivery device technologies. Diabetic pharmaceuticals comprise injectable therapies and oral antidiabetic drugs (OADs). Glucose monitoring device technologies cover blood glucose test strips (BGTS), blood glucose meters, continuous glucose monitoring (CGM) systems, and lancets and lancet devices. Insulin delivery device technologies include insulin pens and needles, insulin pumps, and insulin syringes. By region, the market is segmented into North America (U.S., Canada, Mexico), Europe (Germany, the U.K., Italy, France, Spain, and the Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia-Pacific), the Middle East and Africa (MEA), and South America, focusing on all major countries within these regions.

This study focuses on the driving trends and challenges that affect the market and vendor landscape. It discusses emerging technologies related to the market.

The report concludes by analyzing the competitive landscape and providing leading companies in diabetes therapy, glucose monitoring devices, and insulin delivery devices in the market. It also contains a dedicated section of company profiles that covers company overviews, key financials, product portfolios, and recent developments.

Report Includes

• 116 data tables and 69 additional tables
• An analysis of the current and future global markets for diabetes treatment products and therapeutic innovations
• Analyses of the global market trends, with historic data from 2023 to 2025, estimates for 2026 and projections of CAGRs through 2031
• Estimates of the market size and revenue prospects for the global market, accompanied by a market share analysis by product category, device type, route of administration, and region
• Facts and figures pertaining to the market dynamics, recent technological advancements in diabetes management, regulations, prospects and the impact of macroeconomic variables
• Insights derived from Porter's Five Forces model, as well as global supply chain analyses
• Review of emerging technologies, clinical trials, product and therapeutic innovations and pipeline analysis
• Patent review, featuring key granted and published patents
• Analysis of the industry structure, including companies' market shares and rankings, product mappings, strategic initiatives, M&A activity and a venture funding outlook
• Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
• Company profiles of major players within the industry, including Abbott, Dexcom Inc., Lilly, Medtronic, and Novo Nordisk A/S

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Overview
• Current Market Scenario
• Segmental Analysis
• Regional Analysis
• Technological Advances
• Conclusion

Chapter 2 Market Overview

• Overview
• Epidemiology of Diabetes
• Regional Distribution
• Gender Distribution
• Porter's Five Forces Analysis in the Market for Latest Developments, Product Innovations, and Treatments for Diabetes
• Potential for New Entrants (Low to Moderate)
• Bargaining Power of Suppliers (Low to Moderate)
• Bargaining Power of Buyers (High)
• Threat of Substitutes (Low)
• Competition in the Industry (Low to Moderate)
• Macroeconomic Factor Analysis
• Healthcare Spending
• Insurance Coverage and Reimbursement Policies
• U.S. Tariff Scenario

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Increasing Incidence of Type 1 and Type 2 Diabetes Driven by Urbanization
• Growing Geriatric Population
• Government Initiatives, Screening Programs, and Reimbursement Expansions
• Market Restraints
• Stringent Regulatory and Clinical Validation Requirements
• Limited Healthcare Access in Low- and Middle-Income Countries
• Market Opportunities
• Strategic Collaborations between Pharma, Device, and Digital Health Companies
• Digital Therapeutics and Remote Patient Management Platforms

Chapter 4 Regulatory Landscape

• U.S.
• Anti-Diabetes Drugs
• Diabetes Therapeutic and Diagnostic Devices
• Europe
• Anti-Diabetic Drug
• Diabetic Therapeutic and Diagnostic Devices
• Other Regions
• Anti-Diabetic Drugs
• Diabetic Diagnostics and Therapeutics Devices

Chapter 5 Emerging Technologies and Developments

• Emerging Technologies
• Next-Generation Insulin Delivery Systems
• Non-Invasive Glucose Monitoring
• Artificial Intelligence
• Analysis of Clinical Trials
• Key Takeaways
• Analysis of Clinical Trials by Type of Study
• Clinical Trials Analysis by Status
• Clinical Trials Analysis by Phase
• Patent Analysis
• Key Takeaways
• Patents by Year
• By Leading Applicant
• By Leading Patent Owner
• By Jurisdiction

Chapter 6 Market Segment Analysis

• Segmentation Breakdown
• Market Analysis by Product
• Key Takeaways
• Diabetes Pharmaceuticals
• Glucose Monitoring Device Technologies
• Insulin Delivery Device Technologies
• Geographic Breakdown
• Market Analysis by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• Middle East and Africa (MEA)
• South America

Chapter 7 Competitive Intelligence

• Key Takeaways
• Competitive Landscape
• Leading Companies
• Lilly
• Novo Nordisk A/S
• Abbott
• Dexcom Inc.
• Insulet Corp.
• Medtronic
• Key Developments and Strategies

Chapter 8 Appendix

• Methodology
• Sources
• Abbreviations
• Company Profiles
• ABBOTT
• ACON Laboratories Inc.
• BOEHRINGER INGELHEIM INTERNATIONAL GMBH
• B. BRAUN SE
• DEXCOM INC.
• EMBECTA CORP.
• F. HOFFMANN-LA ROCHE LTD.
• INSULET CORP.
• LILLY
• MEDTRONIC
• NOVO NORDISK A/S
• SENSEONICS
• TANDEM DIABETES CARE INC.
• TERUMO CORP.
• YPSOMED
• Few Emerging Startups/Market Disruptors